BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 19119693)

  • 1. [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].
    Tarantini L; Cioffi G; Di Lenarda A; Valle R; Pulignano G; Del Sindaco D; Frigo G; Soravia G; Tessier R; Catania G
    G Ital Cardiol (Rome); 2008 Dec; 9(12):835-43. PubMed ID: 19119693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides.
    Ng LL; Loke IW; Davies JE; Geeranavar S; Khunti K; Stone MA; Chin DT; Squire IB
    J Am Coll Cardiol; 2005 Apr; 45(7):1043-50. PubMed ID: 15808762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-type Natriuretic Peptide (BNP) is useful in detecting asymptomatic left ventricular dysfunction in low-income, uninsured patients.
    Macabasco-O'Connell A; Meymandi S; Bryg R
    Biol Res Nurs; 2010 Jan; 11(3):280-7. PubMed ID: 19934109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Screening of asymptomatic left ventricular systolic dysfunction in a population sample at high cardiovascular risk in Lombardy (Italy): the DAVID-Berg study].
    Gavazzi A; De Maria R; Grosu A; Iacovoni A; Fontana A; Gori M; Ferrari P; Canova P; Calabrese A; Filippi A; Rutili MR; Donzelli L; Parolini M; Senni M
    G Ital Cardiol (Rome); 2014 May; 15(5):313-22. PubMed ID: 25002172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.
    Ng LL; Pathik B; Loke IW; Squire IB; Davies JE
    Am Heart J; 2006 Jul; 152(1):94-101. PubMed ID: 16824837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients.
    Romano S; Necozione S; Guarracini L; Fratini S; Cisternino P; di Orio F; Penco M
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):238-44. PubMed ID: 19262210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.
    de Lemos JA; McGuire DK; Khera A; Das SR; Murphy SA; Omland T; Drazner MH
    Am Heart J; 2009 Apr; 157(4):746-53.e2. PubMed ID: 19332205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function.
    Valle R; Aspromonte N; Feola M; Milli M; Canali C; Giovinazzo P; Carbonieri E; Ceci V; Cerisano S; Barro S; Milani L
    J Card Fail; 2005 Sep; 11(7):498-503. PubMed ID: 16198244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
    J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Type B natriuretic peptide in the diagnosis of heart failure with preserved systolic function].
    Castro A; Dias P; Pereira M; Pimenta J; Friões F; Rodrigues R; Ferreira A; Bettencourt P
    Rev Port Cardiol; 2001 Nov; 20(11):1109-13. PubMed ID: 11826702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients.
    Post F; Weilemann LS; Messow CM; Sinning C; Münzel T
    Crit Care Med; 2008 Nov; 36(11):3030-7. PubMed ID: 18824903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-type natriuretic peptide testing for structural heart disease screening: a general population-based study.
    Nakamura M; Tanaka F; Sato K; Segawa T; Nagano M
    J Card Fail; 2005 Dec; 11(9):705-12. PubMed ID: 16360967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of the B type natriuretic peptide, electrocardiography, and portable echocardiography for the assessment of patients from the community with suspected heart failure.
    Lim TK; Dwivedi G; Hayat S; Collinson PO; Senior R
    Echocardiography; 2007 Mar; 24(3):228-36. PubMed ID: 17313633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width.
    Goode KM; Clark AL; Cleland JG
    Int J Cardiol; 2008 Nov; 130(3):426-37. PubMed ID: 18178273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinical value of B-type natriuretic peptide in the diagnosis of left heart failure].
    Zhao XY; Yang YJ; Zhang J; Dang AM; Ni XH; Huang J; Kang S; Ma WH; Zhao DY
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(17):1165-9. PubMed ID: 16796855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Brain natriuretic peptide (BNP) in coronary insufficiency: relationship with left ventricular filling and exercise tolerance].
    Logeart D; Gambert A; Beyne P; Guiti C; Geyer C; Bourgoin P; Alonso C; Ennezat PV; Gourgon R; Cohen-Solal A
    Ann Cardiol Angeiol (Paris); 1999 Sep; 48(7):523-8. PubMed ID: 12555377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation.
    Potocki M; Mair J; Weber M; Hamm C; Burkard T; Hiemetzberger R; Peters K; Jander N; Cron TA; Hess N; Hoffmann A; Gekeler H; Gohlke-Bärwolf C; Buser P; Mueller C
    Am J Cardiol; 2009 Aug; 104(4):559-64. PubMed ID: 19660612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular dysfunction screening in hypertensive patients with N-terminal pro-B-type natriuretic peptide and electrocardiogram.
    Limkakeng AT; Drake W; Mani G; Freeman D; Best R; Newby LK; Chandra A
    Am J Emerg Med; 2012 Jan; 30(1):214-7. PubMed ID: 21185671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities.
    Ang DS; Kong CF; Kao MP; Struthers AD
    Am Heart J; 2009 Jul; 158(1):133-40. PubMed ID: 19540403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?
    Galasko GI; Barnes SC; Collinson P; Lahiri A; Senior R
    Eur Heart J; 2006 Jan; 27(2):193-200. PubMed ID: 16267076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.